
In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson goes on to explore how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the potential importance of early and effective therapeutic intervention to alter disease progression
Join Sanofi and Regeneron for an educational symposium on type 2 inflammation, patient characteristics predictive of disease recurrence, and emerging real-world evidence for biologics in CRSwNP.

Learn how the multidimensional, cumulative burdens of atopic dermatitis extend beyond the skin and across multiple organ systems, manifesting as atopic and non-atopic comorbidities. Even when an individual is performing well in spite of these burdens, they may still have significant life course impairment due to the cumulative impact of the disease.

Learn about pediatric EoE disease burden and why early identification is key for pediatric patients with EoE

Learn about pediatric EoE disease burden and why early identification is key for pediatric patients with EoE.
In this webinar, Dr. Butler highlights the complexities of chronic pruritus in older adults, highlighting its prevalence, burden, and the underlying pathophysiological mechanisms, including the role of type 2 inflammation
In this webinar, Dr. Butler highlights the complexities of chronic pruritus in older adults, highlighting its prevalence, burden, and the underlying pathophysiological mechanisms, including the role of type 2 inflammation
Hear Dr. Wechsler and Prof. Bredenoord discuss the multifaceted burden of EoE and how to overcome challenges in identifying EoE in clinical practice.
Professor Matthias Augustin highlights the role of type 2 inflammation in chronic itch across distinct pruritic skin diseases and the cumulative burden of chronic itch and skin lesions in PN.

Join Dr. Victoria Werth in exploring the clinical presentation of BP and how type 2 inflammation contributes to the development of disease signs and symptoms
Join Lisa Swanson, MD, and Gina Mangin, MPAS, PA-C, for an in-depth discussion on the immunopathogenesis of atopic dermatitis (AD), highlighting the central role of key type 2 inflammatory pathways in disease development and progression. This program explores how these pathways contribute to clinical manifestations across the AD spectrum and addresses common perceptions and misconceptions surrounding AD pathomechanisms, offering clarifying insights to support informed clinical decision-making.